Cell specialists chase broad cure
Article Abstract:
The biotechnology firm BresaGen is investigating protein pharmaceuticals for the treatment of horses and researching the use of stem-cells to treat Parkinson's disease. The company shares had dropped in value to 81 cents in Jun 2000 but had risen to $1.60 by Oct 2000.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
CSL seeks a self-cure
Article Abstract:
Australian biotechnology company CSL is having a hard time interesting investors in its research projects, including a cervical cancer vaccine. Investors are concerned more with the low price of plasma, which will affect CSL's earnings and keep its share price down.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Stem-cell surprise
Article Abstract:
The foray of Mesoblast into stem-cell research is examined.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
User Contributions:
Comment about this article or add new information about this topic: